RUA Bioscience Limited Ordinary Shares
RUA.NZXHealth Care
Rua is a New Zealand pharmaceutical company that is aiming to be a leading producer of cannabinoid derived medicines. The Company was established in 2017 in part to support local economic development in the Tairāwhiti (East Coast) region, and is a pioneer in the New Zealand medicinal cannabis sector. It was the first company in New Zealand to obtain a licence to cultivate cannabis for research purposes and the Company’s co-founder was actively involved in both the establishment of the key industry association and the development of the regulatory framework that is now in place to govern the sector. Rua will operate in the research, cultivation, extraction and manufacturing parts of the medicinal cannabis supply chain.
Market Data
$0.030
+0.1%$10.2M
-2.1x
$-0.015
0.00%
+0.1%
Latest Earnings
Half-Year Financial Results: Significant sales growth
27 February 2026
Rua Bioscience reported HY FY26 revenue of NZD $1.33M, a 92% increase over the prior corresponding period, driven by expansion across five markets including Germany, Australia, New Zealand, Czech Republic, and the UK. Despite the strong top-line growth, the net loss before tax improved only marginally to $1.79M from $1.80M, as higher financing costs, non-cash share allocation costs, and stock adjustments offset the revenue gains. The company raised $2.02M (net) via a rights offer and placement, and operating cash outflows improved 22% to $1.52M, though going concern remains a key consideration. Key points: Revenue from customers grew 92% to NZD $1.33M (HY FY26 vs HY FY25), demonstrating strong commercial momentum.; Successfully operating in five international markets: Germany, Australia, New Zealand, Czech Republic, and the UK.; Operating cash outflows improved 22% to $1.52M, reflecting the benefits of the capital-light outsourced manufacturing model.
Recent Announcements
Ongoing Disclosure Notice - Paul Naske
Paul Naske, CEO of Rua Bioscience Limited, acquired 1,400,000 ordinary shares on 21-May-26 as part of a long-term incentive plan at $0.028 per share ($39,200 total consideration), increasing his shareholding from 1,562,372 to 2,962,372 shares.
Capital Change Notice
Rua Bioscience Limited issued 1,400,000 ordinary shares at zero cash consideration to its CEO as part of a long-term incentive plan, representing 0.41% of total shares and warrants on issue, bringing total ordinary shares to 339,441,705.
Rua Bioscience Market Update
Rua Bioscience issued a market update highlighting expansion across five international medicinal cannabis markets, including the establishment of RUA Genetics in Canada and new product launches planned in Czechia and New Zealand, while noting market challenges in Australia due to TGA regulatory review and competitive pressures in Germany following delayed regulation reform.
Expansion into Canada with New Zealand genetics export
Rua Bioscience has expanded into the Canadian market by exporting four cannabis varieties to Canadian nursery Apollo Green in March 2026, marking the first known legal export of live cannabis genetics from New Zealand and first import into Canada. The partnership enables Rua to enter Canada's regulated adult-use cannabis market, valued at approximately CAD$4-5 billion annually.
Half-Year Financial Results: Significant sales growth
Rua Bioscience reported HY FY26 revenue of NZD $1.33M, a 92% increase over the prior corresponding period, driven by expansion across five markets including Germany, Australia, New Zealand, Czech Republic, and the UK. Despite the strong top-line growth, the net loss before tax improved only marginally to $1.79M from $1.80M, as higher financing costs, non-cash share allocation costs, and stock adjustments offset the revenue gains. The company raised $2.02M (net) via a rights offer and placement, and operating cash outflows improved 22% to $1.52M, though going concern remains a key consideration. Key points: Revenue from customers grew 92% to NZD $1.33M (HY FY26 vs HY FY25), demonstrating strong commercial momentum.; Successfully operating in five international markets: Germany, Australia, New Zealand, Czech Republic, and the UK.; Operating cash outflows improved 22% to $1.52M, reflecting the benefits of the capital-light outsourced manufacturing model.
SPH Notice - Gough Investment Capital Ltd
Gough Investment Capital Ltd disclosed a change in substantial holding (5.14%).
SPH Notice - Mr Chu Jun
Mr Chu Jun disclosed a change in substantial holding (7.92%).
Rua Releases Annual Report for Year Ended 30 June 2025
Rua Bioscience reported FY25 revenue of NZD $1.90m, a significant increase from $0.32m in FY24, driven by growing commercial traction across five international markets including Australia, New Zealand, Germany, UK, and Czechia. The loss before tax narrowed substantially to $3.46m from $13.72m in FY24, reflecting improved operational efficiency. However, the company flagged a material going concern risk, noting insufficient cash to meet minimum expenditure commitments without raising additional capital. Key points: Revenue surged ~494% to NZD $1.90m in FY25 (FY24: $0.32m), with customer revenue reaching $1.51m (FY24: $86K).; Loss before tax reduced dramatically to $3.46m from $13.72m in FY24, a ~75% improvement.; Commercial presence established across five international markets: Australia, New Zealand, Germany, UK, and Czechia.
Preliminary Unaudited Annual Results
Rua Bioscience (NZX: RUA) reported a significant turnaround in revenue for FY25, with revenue from customers growing to NZD $1.51M from just $86K in FY24, driven by expansion in Germany, Australia, and New Zealand. The loss before tax narrowed sharply to $3.46M from $13.72M in FY24, largely due to the absence of large impairment charges seen last year, with the underlying loss before impairment also improving from $4.50M to $3.42M. Going concern risks remain material, with the company dependent on ongoing shareholder funding, a planned facility sale, and continued revenue growth to sustain operations. Key points: Revenue from customers grew dramatically from NZD $86K to $1.51M (>17x increase), demonstrating the export-led strategy gaining real traction.; Total loss before tax reduced by 74.8% from $13.72M to $3.46M, with the underlying loss (excluding impairments) improving from $4.50M to $3.42M.; Successfully established distribution agreements and clinic partnerships in Germany, Australia, New Zealand, UK, and new entrant market Czechia.
Rua Bioscience Half Year Results data
Rua Bioscience reported a significant improvement in its half-year results to 31 December 2024, with revenue surging 529% to NZD $889K compared to the prior corresponding period. The net loss from continuing operations improved by 83% to NZD $1.802M, indicating meaningful progress in reducing cash burn. No dividend was declared, consistent with the company's early-stage growth profile. Key points: Revenue from continuing operations surged 529% to NZD $889K, signalling strong commercial momentum; Net loss improved by 83% year-on-year to NZD $1.802M, demonstrating meaningful reduction in cash burn; Loss reduction suggests improving operational efficiency as the business scales
Get real-time alerts for RUA
Receive AI-powered earnings summaries and instant notifications when RUA Bioscience Limited Ordinary Shares releases results.
Register Free